Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Agila Unit In India Issues U.K. Recall For Injectable Antibiotic

This article was originally published in PharmAsia News

Executive Summary

Another India drug-production site has become the source of a recall, this one producing batches of an injectable antibiotic for Mylan and its Agila unit of Strides Arcolab International.

You may also be interested in...



J&J Faces Fraud Claims From Merger With Surgical Robot Firm

Investors in surgical robotics company Auris say Johnson & Johnson failed to support the company per their merger agreement.

As Pandemic Boosts Demand For Immunity Supplements, Dentovations Launches Self+ Line

based firm, which markets Activa hand sanitizers, is offering Self+ immunity supplements in Brain, Energy and Unwind formulations in powder format for mixing with water.

Pink Sheet Podcast: The Big Vaccines Adcomm, AMAG Fights Makena Withdrawal

Pink Sheet reporters and editors discuss their take-aways from the recent advisory committee meeting on coronavirus vaccine development and approval, as well as the upcoming FDA hearing on Makena’s withdrawal.

Topics

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel